Please login to the form below

Not currently logged in
Email:
Password:

Zelluna Immunotherapy appoints chief technology officer

Arjan Roozen will consolidate the biotech’s manufacturing strategy

Norwegian biotech Zelluna Immunotherapy has bolstered its offering with the appointment of a new chief technology officer.

Arjan Roozen, who previously headed up the GMP solutions and manufacturing team at French cell therapy group Cellectis, comes with expertise in microbiology and molecular microbiology.

Roozen’s career history has also seen him serve in numerous positions for Pharmacell, which was recently acquired by Lonza.

Miguel Forte, chief executive officer of Zelluna, said: “Zelluna appointed Arjan specifically for his wide-ranging knowledge in key areas of cell therapy product manufacturing.

“His experience, acquired on both side’s of the Atlantic will provide invaluable for Zelluna in its immediate focus of delivering clinical proof of concept of its TCRs in adoptive cell therapy for solid cancers.

“He will play a big part in the execution of Zelluna’s manufacturing strategy for clinical trials and commercialisation.”

20th April 2018

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
bmore group

OUR PROMISE: BETTER HEALTH FROM TRIAL TO TREATMENT.We are a full service, independent network of specialist agencies under one roof....

Latest intelligence

Cutting through the noise
AstraZeneca looks to lead an R&D revolution as the company invests in CRISPR and functional genomics drug discovery...
International Childhood Cancer Day 2019
The number of new cases per year is shocking but the journey and the outlooks have vastly improved. We've pulled together an infographic to show just what we mean with...
Immuno-oncology in 2019: the rapid evolution continues
Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...

Infographics